An observational study in Liver Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.
Among the 93 studies in Liver Neoplasms with a site in France, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2023, is one of 26 observational ones, reaches primary completion later than 4 of the 27 other live ones, and was the 85th registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18–100
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 28 · Phase 3 21
First in 1999; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 344 observational studies indexed under Liver Neoplasms.
Median enrollment 129 across the 66 interventional studies, 303 across the 26 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 93 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 9 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Liver Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03408665Centre Oscar LambretStereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | 2026-12-01 |
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Liver Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Irreversible electroporation is a curative treatment for cancerous liver lesions, performed on deep-seated tumors that are not eligible for surgical resection or percutaneous thermal ablation.
The EVALHEP project aims to develop criteria for evaluating the effectiveness of the treatment based on imaging, mathematical models, and numerical simulations to assist radiologists who perform these complex procedures.
Percutaneous destruction of malignant liver tumors has been developing in routine clinical practice for around twenty years, and is performed by interventional radiologists under imaging guidance (ultrasound, computed tomography (CT), Cone-Beam CT...).
Irreversible electroporation (IRE) is a percutaneous tumor destruction technique distinguished from other ablation methods by its non-thermal mechanism of action. The rationale behind IRE is that cells subjected to a powerful pulsed electric field will have their membrane irreversibly damaged and destroyed, while the surrounding extracellular matrix will be respected. This technology offers the opportunity to effectively destroy lesions that would be impossible to treat by any other method, due to their critical tumor location, close to vital structures at risk.
Although it has demonstrated its clinical efficacy over the years, with the potential to provide safe, curative treatment for patients with deep, poorly located tumors, IRE is considered a complex procedure, subject to numerous variability factors, and remains under-utilized to this day. Precise insertion of several needles (up to 6) at tumor level is required to obtain a homogeneous electric field of sufficient intensity. To date, there is no way of assessing the effectiveness of the procedure in real time, and inaccuracies in needle positioning or in treatment parameters will generate changes in the distribution of the electric field that may adversely affect treatment efficacy. What's more, it remains difficult to assess treatment efficacy on post-therapy images, the interpretation of which is subject to controversy.
The Interventional Radiology (IR) unit of the University Hospitals of Paris Seine Saint Denis (HUPSSD) has been using IRE for over 10 years as part of its clinical routine, mainly for the ablation of liver tumors, and in particular hepatocellular carcinoma (HCC) which is inoperable and ineligible for conventional thermo-ablation. Over the past ten years, more than 350 patients have benefited from one or more IREs for the treatment of liver tumors at HUPSSD, making the department a reference center in the field.
Thanks to the contributions of mathematics applied to oncology, numerical tools and the clinical experience of the HUPSSD IR department, the aim of this project is to develop evaluation criteria for IRE ablations of liver tumors based on clinical imaging and numerical simulations of the electric field.
Patients with liver cancer (hepatocellular carcinoma) treated by IRE between 2022 and 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of malignant liver tumor based on either :
Complete peri-interventional imaging file including:
Cone-Beam CT (CBCT) volume reconstructions acquired during the IRE procedure available and including at least :
Exclusion Criteria:
to MRI:
Contraindication to percutaneous IRE treatment due to :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up
Demonstrate a correlation between the treatment zones segmented on post-therapy MRI scans and the three-dimensional electric field isolines obtained using digital simulations.
Time frame: 72 hours and 1 month after treatment
Calculation of the tumor coverage rate by the various electric field isolines at different relevant values (for example, three-dimensional isolines between 300 and 700V.cm-1 will be simulated numerically).
Determine a threshold for IRE of liver tumors by combining numerical electric field resolution and post-treatment imaging data.
Time frame: 72 hours and 1 month after treatment
Correlation of recovery rate with treatment outcome and local recurrence during clinical follow-up
Assess inter-individual variations in liver and tumor conductivity values based on impedance data provided by the IRE generator.
Time frame: 72 hours and 1 month after treatment
Identification and assessment of imaging biomarkers (radiomics-based) using numerical simulation and post-therapeutic imaging for treatment response evaluation.
Determine a threshold electric field value to be reached for complete treatment (calculation of sensitivity, specificity, PPV, NPV, ROC curve)
Time frame: 72 hours and 1 month after treatment
Digital resolution of electrical potential and tissue conductivity values from test pulses at the start of the procedure.
Evaluate the most suitable and clinically relevant numerical electroporation model (linear/non-linear, static/dynamic).
Time frame: 72 hours and 1 month after treatment
Develop software solutions potentially usable in real-time and tailored for clinical use.
Demonstrate a correlation between the treatment zones segmented on post-therapy MRI
Time frame: 72 hours and 1 month after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for May 2025, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →